New developments in heart failure: Role of endothelin and the use of endothelin receptor antagonists

Journal of Cardiac Failure

Volumn 6, Issue 4, 2000, Pages 359-368

  Suresh, D P ^a   Lamba, S ^a   Abraham, W T ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Endothelin; Heart failure; Receptor antagonists

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; NEUROHORMONE; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; HEART FAILURE; HEMODYNAMICS; LONG TERM CARE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BLOCKING; REVIEW;

EID: 0034519401     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2000.20560     Document Type: Article

References (75)

1. Economic impact of heart failure in the United States: Time for a different approach
2. Epidemiological aspects of heart failure
3. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults
4. Economic impact of heart failure in the United States: Time for a different approach
5. The healthcare economics heart failure
6. Trends in hospitalization for heart failure in the United States, 1973-1986: Evidence for increasing population prevalence
7. Effects of enalapril on mortality in severe congestive heart failure
8. Effect of oral milrinone on mortality in severe chronic heart failure
9. Effect of amlodipine on morbidity and mortality in severe heart failure
10. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure
11. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
12. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study
13. The The effect of digoxin on mortality and morbidity in patients with heart failure
14. Cost-effective cardiology: Cost-effective management of heart failure
15. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies
16. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
17. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
18. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
19. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
20. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Intervention Trial in Congestive Heart Failure (MERIT-HF)
21. Consensus recommendations for the management of chronic heart failure
22. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
23. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells
24. Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture
25. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
26. Endothelins: Biochemistry and pathophysiologic actions
27. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured vascular endothelial cells by inhibiting a big endothelin-1 converting enzyme
28. Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells
29. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells
30. Transforming growth factor beta stimulates expression of endothelin mRNA by vascular endothelial cells
31. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells
32. Increased plasma and pulmonary lymph levels of endothelin during endotoxic shock
33. Endotoxin stimulates endothelin release in vivo and in vitro as determined by radioimmunoassay
34. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium
35. Smooth muscle cells contain a factor responsible for decreasing big endothelin and endothelin-1 production by cultured endothelial cells
36. Endothelin receptor is coupled to phospholipase C via a pertussis toxin insensitive guanine nucleotide regulatory protein in vascular smooth muscles
37. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
38. B receptors in local clearance of endothelin-1 in rat heart. Studies with antagonist PD 155080 and BQ-788
39. Endothelin activated the di-hydropyridine-sensitive, voltage-dependent Ca channel in vascular smooth muscle
40. Endothelin action: Inhibition by a protein kinase C inhibitor and involvement of phosphoinositols
41. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
42. Hemodynamic effect of human and rat endothelin administration into conscious rats
43. Pressor effects of endothelin-1 and some analogs in the perfused mesenteric arterial bed of the rat
44. Increased endothelin in experimental heart failure
45. Endothelin in experimental congestive heart failure in the anesthetized dog
46. Plasma endothelin in chronic heart failure
47. Endothelin in human congestive heart failure
48. Plasma endothelin concentrations are increased in humans with congestive heart failure
49. Endothelin in experimental congestive heart failure in the anesthetized dog
50. Endothelin stimulates protein synthesis in smooth muscle cells
51. Endogenous endothelin- 1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart
52. Differential regulation of fos and jun gene expresiion and AP 1 cis element activity by endothelin peptides. Possible implication of mitogenic signaling by endothelin
53. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathology
54. B receptor mediates both vasodilation and vasoconstriction in vivo
55. Endothelium-dependent modulation of responses to endothelin-1 in human veins
56. Both ETA and ETB receptors mediate contraction to endothelin- 1 in human blood vessels
57. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
58. Clearance of circulating endothelin-1 by ETB receptors in rats
59. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ET(B) receptors
60. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure
61. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET(A) receptor blockade in chronic heart failure patients treated with ACE inhibitors
62. Impaired vasoconstriction to endothelin-1 in small arteries from patients with congestive heart failure
63. Cardiovascular actions of ET-B activation in vivo and modulation by receptor antagonism
64. Effects of endothelin on collagen turnover in cardiac fibroblasts
65. Endothelin B receptors are functionally important in mediating vasoconstriction in patients with left ventricular systolic dysfunction
66. Endothelin clearance in patients with chronic heart failure: Implications for antiendothelin therapy
67. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
68. Chronic endothelin-1 blockade preserves myocardial contractility in dilated cardiomyopathy
69. Comparison of the acute effects of a selective endothelin ET-A and a mixed ET-A/B receptor antagonist in heart failure
70. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
71. Multicenter, doubleblind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial
72. Long-term open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure
73. Acute hemodynamic and neurohumoral effects of selective ET-A receptor blockade in patients with congestive heart failure
74. Improved hemodynamics with the ET-A selective receptor antagonist BMS-193884 in patients with heart failure